143 related articles for article (PubMed ID: 30308032)
1. Impact of the duration of the evidence-based medicine use in acute heart failure: A nationwide cohort study.
Wu WT; Chu CY; Hsu PC; Lee WH; Su HM; Yen HW; Voon WC; Lai WT; Sheu SH; Lin TH
PLoS One; 2018; 13(10):e0205440. PubMed ID: 30308032
[TBL] [Abstract][Full Text] [Related]
2. Evidence-based pharmacotherapies used in the postdischarge phase are associated with improved one-year survival in senior patients hospitalized with heart failure.
Qin X; Hung J; Knuiman M; Teng TK; Briffa T; Sanfilippo FM
Cardiovasc Ther; 2018 Dec; 36(6):e12464. PubMed ID: 30126048
[TBL] [Abstract][Full Text] [Related]
3. Effect of Beta-blocker therapy on rehospitalization rates in women versus men with heart failure and preserved ejection fraction.
Farasat SM; Bolger DT; Shetty V; Menachery EP; Gerstenblith G; Kasper EK; Najjar SS
Am J Cardiol; 2010 Jan; 105(2):229-34. PubMed ID: 20102924
[TBL] [Abstract][Full Text] [Related]
4. Comparison of one-year outcome (death and rehospitalization) in hospitalized heart failure patients with left ventricular ejection fraction >50% versus those with ejection fraction <50%.
Ezekowitz JA; Lee DS; Tu JV; Newman AM; McAlister FA
Am J Cardiol; 2008 Jul; 102(1):79-83. PubMed ID: 18572040
[TBL] [Abstract][Full Text] [Related]
5. Uptitration of renin-angiotensin system blocker and beta-blocker therapy in patients hospitalized for heart failure with reduced versus preserved left ventricular ejection fractions.
Verbrugge FH; Duchenne J; Bertrand PB; Dupont M; Tang WH; Mullens W
Am J Cardiol; 2013 Dec; 112(12):1913-20. PubMed ID: 24286620
[TBL] [Abstract][Full Text] [Related]
6. Outcomes in patients hospitalized for heart failure and chronic obstructive pulmonary disease: differences in clinical profile and treatment between 2002 and 2009.
Staszewsky L; Cortesi L; Tettamanti M; Dal Bo GA; Fortino I; Bortolotti A; Merlino L; Latini R; Roncaglioni MC; Baviera M
Eur J Heart Fail; 2016 Jul; 18(7):840-8. PubMed ID: 27098360
[TBL] [Abstract][Full Text] [Related]
7. Retrospective claims database analysis to determine relationship between renin-angiotensin system agents, rehospitalization, and health care costs in patients with heart failure or myocardial infarction.
Sun SX; Ye X; Lee KY; Dupclay L; Plauschinat C
Clin Ther; 2008; 30 Pt 2():2217-27. PubMed ID: 19281916
[TBL] [Abstract][Full Text] [Related]
8. Comparative effectiveness of beta-adrenergic antagonists (atenolol, metoprolol tartrate, carvedilol) on the risk of rehospitalization in adults with heart failure.
Go AS; Yang J; Gurwitz JH; Hsu J; Lane K; Platt R
Am J Cardiol; 2007 Aug; 100(4):690-6. PubMed ID: 17697830
[TBL] [Abstract][Full Text] [Related]
9. Association of β-blocker therapy with risks of adverse cardiovascular events and deaths in patients with ischemic heart disease undergoing noncardiac surgery: a Danish nationwide cohort study.
Andersson C; Mérie C; Jørgensen M; Gislason GH; Torp-Pedersen C; Overgaard C; Køber L; Jensen PF; Hlatky MA
JAMA Intern Med; 2014 Mar; 174(3):336-44. PubMed ID: 24247428
[TBL] [Abstract][Full Text] [Related]
10. Carvedilol use at discharge in patients hospitalized for heart failure is associated with improved survival: an analysis from Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF).
Fonarow GC; Abraham WT; Albert NM; Stough WG; Gheorghiade M; Greenberg BH; O'Connor CM; Sun JL; Yancy C; Young JB;
Am Heart J; 2007 Jan; 153(1):82.e1-11. PubMed ID: 17174643
[TBL] [Abstract][Full Text] [Related]
11. Predictors of mortality after discharge in patients hospitalized with heart failure: an analysis from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF).
O'Connor CM; Abraham WT; Albert NM; Clare R; Gattis Stough W; Gheorghiade M; Greenberg BH; Yancy CW; Young JB; Fonarow GC
Am Heart J; 2008 Oct; 156(4):662-73. PubMed ID: 18926148
[TBL] [Abstract][Full Text] [Related]
12. Incidence and predictors of rehospitalization of acute heart failure patients.
Kaneko H; Suzuki S; Goto M; Arita T; Yuzawa Y; Yagi N; Murata N; Kato Y; Kano H; Matsuno S; Otsuka T; Uejima T; Oikawa Y; Sagara K; Nagashima K; Kirigaya H; Sawada H; Aizawa T; Yajima J; Yamashita T
Int Heart J; 2015; 56(2):219-25. PubMed ID: 25740584
[TBL] [Abstract][Full Text] [Related]
13. Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: the ASTRONAUT randomized trial.
Gheorghiade M; Böhm M; Greene SJ; Fonarow GC; Lewis EF; Zannad F; Solomon SD; Baschiera F; Botha J; Hua TA; Gimpelewicz CR; Jaumont X; Lesogor A; Maggioni AP;
JAMA; 2013 Mar; 309(11):1125-35. PubMed ID: 23478743
[TBL] [Abstract][Full Text] [Related]
14. Clinical effectiveness of beta-blockers in heart failure: findings from the OPTIMIZE-HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure) Registry.
Hernandez AF; Hammill BG; O'Connor CM; Schulman KA; Curtis LH; Fonarow GC
J Am Coll Cardiol; 2009 Jan; 53(2):184-92. PubMed ID: 19130987
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and tolerability of adding an angiotensin receptor blocker in patients with heart failure already receiving an angiotensin-converting inhibitor plus aldosterone antagonist, with or without a beta blocker. Findings from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial.
Weir RA; McMurray JJ; Puu M; Solomon SD; Olofsson B; Granger CB; Yusuf S; Michelson EL; Swedberg K; Pfeffer MA;
Eur J Heart Fail; 2008 Feb; 10(2):157-63. PubMed ID: 18242128
[TBL] [Abstract][Full Text] [Related]
16. N-terminal pro-B-type natriuretic peptide-guided, intensive patient management in addition to multidisciplinary care in chronic heart failure a 3-arm, prospective, randomized pilot study.
Berger R; Moertl D; Peter S; Ahmadi R; Huelsmann M; Yamuti S; Wagner B; Pacher R
J Am Coll Cardiol; 2010 Feb; 55(7):645-53. PubMed ID: 20170790
[TBL] [Abstract][Full Text] [Related]
17. In-hospital and 1-year outcomes of acute heart failure patients according to presentation (de novo vs. worsening) and ejection fraction. Results from IN-HF Outcome Registry.
Senni M; Gavazzi A; Oliva F; Mortara A; Urso R; Pozzoli M; Metra M; Lucci D; Gonzini L; Cirrincione V; Montagna L; Di Lenarda A; Maggioni AP; Tavazzi L;
Int J Cardiol; 2014 May; 173(2):163-9. PubMed ID: 24630337
[TBL] [Abstract][Full Text] [Related]
18. Influence of beta-blocker continuation or withdrawal on outcomes in patients hospitalized with heart failure: findings from the OPTIMIZE-HF program.
Fonarow GC; Abraham WT; Albert NM; Stough WG; Gheorghiade M; Greenberg BH; O'Connor CM; Sun JL; Yancy CW; Young JB;
J Am Coll Cardiol; 2008 Jul; 52(3):190-9. PubMed ID: 18617067
[TBL] [Abstract][Full Text] [Related]
19. Current use of guideline-based medical therapy in elderly patients admitted with acute heart failure with reduced ejection fraction and its impact on event-free survival.
Akita K; Kohno T; Kohsaka S; Shiraishi Y; Nagatomo Y; Izumi Y; Goda A; Mizuno A; Sawano M; Inohara T; Fukuda K; Yoshikawa T;
Int J Cardiol; 2017 May; 235():162-168. PubMed ID: 28259550
[TBL] [Abstract][Full Text] [Related]
20. β-Blockers in Atrial Fibrillation Patients With or Without Heart Failure: Association With Mortality in a Nationwide Cohort Study.
Nielsen PB; Larsen TB; Gorst-Rasmussen A; Skjøth F; Lip GY
Circ Heart Fail; 2016 Feb; 9(2):e002597. PubMed ID: 26823497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
